Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Linton

Showing results (251-260 of 265) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2017
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaMyron S Czuczman, Marek Trněný, Andrew Davies, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Pathogens spread by high-altitude windborne mosquitoesR Bamou, A Dao, A S Yaro, et al.
Haematologica|October 27, 2022
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphomaJahanzaib Khwaja, Amy A Kirkwood, Lisa K Isbell, et al.
Nature|December 6, 2019
Near-Sun observations of an F-corona decrease and K-corona fine structureR A Howard, A Vourlidas, V Bothmer, et al.
Lancet (London, England)|December 10, 2025
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trialLorenzo Falchi, Marcel Nijland, Huiqiang Huang, et al.
The Lancet. Haematology|June 18, 2024
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre studyKim M Linton, Umberto Vitolo, Wojciech Jurczak, et al.
Neuromuscular Disorders : NMD|October 14, 2014
Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophiesKatherine G Meilleur, Minal S Jain, Linda S Hynan, et al.
The Lancet. Haematology|May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Blood|October 13, 2023
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphomaPietro R Di Ciaccio, Mark N Polizzotto, Kate Cwynarski, et al.
The Lancet. Haematology|October 22, 2017
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Pageof 27

Showing results (251-260 of 265) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2017
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaMyron S Czuczman, Marek Trněný, Andrew Davies, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Pathogens spread by high-altitude windborne mosquitoesR Bamou, A Dao, A S Yaro, et al.
Haematologica|October 27, 2022
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphomaJahanzaib Khwaja, Amy A Kirkwood, Lisa K Isbell, et al.
Nature|December 6, 2019
Near-Sun observations of an F-corona decrease and K-corona fine structureR A Howard, A Vourlidas, V Bothmer, et al.
Lancet (London, England)|December 10, 2025
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trialLorenzo Falchi, Marcel Nijland, Huiqiang Huang, et al.
The Lancet. Haematology|June 18, 2024
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre studyKim M Linton, Umberto Vitolo, Wojciech Jurczak, et al.
Neuromuscular Disorders : NMD|October 14, 2014
Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophiesKatherine G Meilleur, Minal S Jain, Linda S Hynan, et al.
The Lancet. Haematology|May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Blood|October 13, 2023
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphomaPietro R Di Ciaccio, Mark N Polizzotto, Kate Cwynarski, et al.
The Lancet. Haematology|October 22, 2017
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Pageof 27